According to the conference calls, as of October 1, 2014 Novadaq had 41 sales professionals and 6 clinical specialists, by the end of of that year this had gone to 75 sales professionals and 25 clinical specialists.
By March 31, 2015 this had grown to 78 sales professionals and 29 clinical specialists.
Being a Canadian company, Novadaq's financial reporting isn't always available from the usual outlets. However, I'm seeing some insider buys from both Dr. Arun Menawat (~15,000 shares, May 4 and 11) and Roger Deck (40,000 shares, May 1). Nice to see them stepping up!
Agreed, he was very positive and reaffirmed 2015 revenue guidance. Did you catch that compared to last year's slide on targeted SPY procedures, the total has risen from 1.7 million to 2.0 million? The difference lies with splitting out lymphatic into its own category with 400,000 procedures and dropping gynecology back from 200,000 to 100,000.
At the end of April, in the investors section of their website, Novadaq released a new letter from Arun. It discusses events of the last couple of years, studies (completed and in progress), partners, patents (89 granted and 102 pending), and the direction of the company's future efforts.
The cushion just seems a little... cushy. Novadaq has a $25M annual burn rate now. At that pace it would take five years to run through the cash. If we didn't see positive cash flow in a year I'd be thoroughly amazed.
In October of 2013 Novadaq placed a stock offering at $16.75 per share, gaining $105M. At the time it was billed as paving the way for future acquisitions or buying complementary businesses. It was thought that they were about to buy a business to acquire a fully functioning sales staff. This never happened and Novadaq filled out their own sales team.
As of last quarter they still had $141M in cash. We are now $4 or 25% below the offering price. Is it time for the company to reinvest some of this money with a partial buy back? Or at least authorize one to open the option?
I thought the post was near to inviting a lawsuit, may be the author rethought it and got cold feet. Or maybe a complaint was filed and Yahoo took it down. I have seen other controversial posts disappear.
Yahoo terms of service -
You agree to not use the Yahoo Services to upload, post, email, transmit, or otherwise make available any Content that is unlawful, harmful, threatening, abusive, harassing, tortious, defamatory, vulgar, obscene, libelous, invasive of another's privacy, hateful, or racially, ethnically, or otherwise objectionable;
Before getting too excited, this may be a quietly discontinued product. There is a reference in the 2009 Q4 statement to a write down of the OPTTX intangible asset and inventory. Sorry if I didn't perform adequate DD before posting.
I was totally unaware that Novadaq makes a device (known as the OPTTX System, CE Mark 2006) to diagnose and treat age-related, wet Macular Degeneration. Evidently, the system combines SPY imaging technology and cauterization. Most web information about it from the 2005-2008 era, mostly trial and study references, but announcement information was from prnewswire. A term search of the company website with "optxx" or "macular" came up with zero hits.
I, too, thought the percentage split was in reference to the status of the SPY Elite accounts at handover and not an indictment of the sales teem.
I agree with the lack of news comment. With the exception of the pre-announcement of earnings and the conference call there has been amazingly little news over the last three months. The investor conferences have revealed little more than what was already known.
Maybe SAGES 2015 (April 14-18) will get the ball rolling.